| Literature DB >> 36111071 |
Alfred Kipyegon Keter1,2,3, Lutgarde Lynen1, Alastair Van Heerden2,4, Els Goetghebeur3, Bart K M Jacobs1.
Abstract
Background: In application studies of latent class analysis (LCA) evaluating imperfect diagnostic tests, residual dependence among the diagnostic tests still remain even after conditioning on the true disease status due to measured variables known to affect prevalence and/or alter diagnostic test accuracy. Presence of severe comorbidities such as HIV in pulmonary tuberculosis (PTB) diagnosis alter the prevalence of PTB and affect the diagnostic performance of the available imperfect tests in use. This violates two key assumptions of LCA: (1) that the diagnostic tests are independent conditional on the true disease status (2) that the sensitivity and specificity remain constant across subpopulations. This leads to incorrect inferences.Entities:
Keywords: Bayesian latent class analysis; Prevalence; Sensitivity; Simulation; Specificity; Tuberculosis
Year: 2022 PMID: 36111071 PMCID: PMC9468460 DOI: 10.1016/j.jctube.2022.100331
Source DB: PubMed Journal: J Clin Tuberc Other Mycobact Dis ISSN: 2405-5794
Fig. 1Graphical presentation of the working models.
Frequentist evaluation of Bayesian estimates of total population pulmonary tuberculosis (PTB) prevalence obtained using four working models in the analysis of five and three diagnostic test results.
| Five diagnostic tests | ||||||
|---|---|---|---|---|---|---|
| Model | N | True value | Median (95% RI) | Mean (95% CI) | RMSEx100 | Coverage |
| I | 1000 | 6·0 | 6·3 (4·4, 8·9) | 6·4 (6·1, 6·6) | 1·2 | 95·0 |
| 2000 | 6·0 | 6·1 (5·0, 7·3) | 6·1 (6·0, 6·2) | 0·6 | 95·0 | |
| 5000 | 6·0 | 6·0 (5·2, 6·9) | 6·9 (5·2, 8·6) | 8·8 | 93·0 | |
| II | 1000 | 6·0 | 7·3 (5·5, 10·6) | 7·5 (7·1, 7·8) | 2·3 | 81·0 |
| 2000 | 6·0 | 6·5 (5·1, 7·9) | 6·5 (6·4, 6·6) | 0·8 | 90·0 | |
| 5000 | 6·0 | 6·2 (5·4, 6·9) | 6·2 (6·1, 6·3) | 0·4 | 93·0 | |
| III | 1000 | 6·0 | 6·4 (4·4, 11·4) | 6·6 (6·3, 6·9) | 1·7 | 94·0 |
| 2000 | 6·0 | 6·0 (4·7, 7·4) | 6·0 (5·9, 6·1) | 0·7 | 93·0 | |
| 5000 | 6·0 | 5·9 (5·2, 6·7) | 5·9 (5·9, 6·0) | 0·4 | 95·0 | |
| IV | 1000 | 6·0 | 6·7 (4·7, 9·5) | 6·8 (6·5, 7·1) | 1·6 | 93·0 |
| 2000 | 6·0 | 6·2 (4·8, 7·7) | 6·3 (6·1, 6·4) | 0·7 | 93·0 | |
| 5000 | 6·0 | 6·1 (5·3, 6·9) | 6·1 (6·0, 6·2) | 0·4 | 94·0 | |
| Three diagnostic tests | ||||||
| Model | N | True value | Median (95% RI) | Mean (95% CI) | RMSEx100 | Coverage |
| I | 1000 | 6·0 | 5·7 (3·0, 16·2) | 6·6 (5·9, 7·3) | 3·4 | 96·0 |
| 2000 | 6·0 | 6·1 (4·0, 13·1) | 6·6 (6·2, 7·1) | 2·4 | 98·0 | |
| 5000 | 6·0 | 6·7 (4·4, 12·7) | 7·3 (6·8, 7·7) | 2·4 | 94·0 | |
| II | 1000 | 6·0 | 23·1 (7·0, 39·8) | 23·4 (21·7, 25·1) | 19·4 | 17·0 |
| 2000 | 6·0 | 23·0 (14·6, 37·3) | 24·0 (22·8, 25·2) | 19·0 | 0·0 | |
| 5000 | 6·0 | 25·5 (18·7, 36·3) | 26·1 (24·8, 27·4) | 21·2 | 0·0 | |
| III | 1000 | 6·0 | 4·9 (2·7, 12·9) | 5·3 (4·8, 5·8) | 2·5 | 94·0 |
| 2000 | 6·0 | 5·0 (3·2, 8·5) | 5·3 (5·0, 5·5) | 1·6 | 98·0 | |
| 5000 | 6·0 | 5·6 (3·8, 10·5) | 5·9 (5·6, 6·2) | 1·6 | 92·0 | |
| IV | 1000 | 6·0 | 5·1 (2·9, 15·2) | 5·7 (5·1, 6·4) | 3·2 | 96·0 |
| 2000 | 6·0 | 5·4 (3·5, 8·0) | 5·5 (5·2, 5·7) | 1·3 | 99·0 | |
| 5000 | 6·0 | 5·6 (4·1, 8·2) | 5·7 (5·4, 5·9) | 1·2 | 95·0 | |
N – Sample size.
RI – Reference Intervals and was calculated as the 2·5% and 97·5% percentiles of the distribution of median estimates of the posterior distributions from the one hundred replicate datasets.
CI – Confidence Intervals.
RMSE – Root Mean Square Error.
Five diagnostic tests: any PTB symptom, CAD4TB, CRP, culture and Xpert MTB/RIF.
Three diagnostic tests: any PTB symptom, CAD4TB and Xpert MTB/RIF.
Model I – Model restricting PTB prevalence and the diagnostic test accuracy to remain constant across the HIV subpopulations.
Model II – Model allowing PTB prevalence but not the diagnostic test accuracy to vary across the HIV subpopulations.
Model III – Model restricting PTB prevalence but not the diagnostic test accuracy to remain constant across the HIV subpopulations.
Model IV – Model allowing PTB prevalence and the diagnostic test accuracy to vary across the HIV subpopulations.
Fig. 2Median (95% reference intervals (RI)) and mean (95% confidence intervals (CI)) estimates of total population sensitivity (left) and specificity (right) with corresponding root mean squared error (RMSE) and coverages of 95% credible intervals (CrI) for true total population sensitivity and specificity for five diagnostic tests evaluated using working model I (top panel) and working model II (lower panel) – Working model I restricts the diagnostic test accuracy and disease prevalence to remain constant across the HIV subpopulations, Working model II restricts the diagnostic test accuracy to remain constant but allows the disease prevalence to vary across the HIV subpopulations.
Fig. 3Median (95% reference intervals (RI)) and mean (95% confidence intervals (CI)) estimates of sensitivity (left) and specificity (right) for HIV+ (top panel) and HIV− (lower panel) with corresponding root mean squared error (RMSE) and coverages of 95% credible intervals (CrI) for true sensitivity and specificity for five diagnostic tests evaluated using the model allowing the diagnostic test accuracy and disease prevalence to vary across the HIV subpopulations (working model IV).
Fig. 4Median (95% reference intervals (RI)) and mean (95% confidence intervals (CI)) estimates of sensitivity (left) and specificity (right) for HIV+ (top panel) and HIV− (lower panel) with corresponding root mean squared error (RMSE) and coverages of 95% credible intervals (CrI) for true sensitivity and specificity for three diagnostic tests evaluated using the model allowing the diagnostic test accuracy and disease prevalence to vary across the HIV subpopulations (working model IV).